Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas

NCT05392374 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2022-05-26

No results posted yet for this study

Summary

This is an intermediate-size expanded access protocol to provide ONC201 to patients with diffuse intrinsic pontine gliomas who cannot access ONC201 through clinical trials.

Conditions

Interventions

DRUG

ONC201

ONC201 is an oral, small molecule selective antagonist of DRD2

Sponsors & Collaborators

Eligibility

Min Age
6 Months
Max Age
18 Years
Sex
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05392374 on ClinicalTrials.gov